Validation of in-house knowledge-based planning model for predicting change in target coverage during VMAT radiotherapy to in-operable advanced-stage NSCLC patients-Reference-Cited by-同舟云学术

Validation of in-house knowledge-based planning model for predicting change in target coverage during VMAT radiotherapy to in-operable advanced-stage NSCLC patients

Published:2021-09-02 Issue:6 Volume:7 Page:065002
ISSN:2057-1976
Container-title:Biomedical Physics & Engineering Express
language:
Short-container-title:Biomed. Phys. Eng. Express

Author:

Tambe Nilesh S^ORCID,Pires Isabel M,Moore Craig^ORCID,Wieczorek Andrew,Upadhyay Sunil,Beavis Andrew W^ORCID

Publisher

IOP Publishing

Subject

General Nursing

Link

https://iopscience.iop.org/article/10.1088/2057-1976/ac1f94/pdf

Reference25 articles.

1. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC;Antonia;N. Engl. J. Med.,2018

2. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer;Antonia;N. Engl. J. Med.,2017

3. Adaptive radiotherapy for locally advanced non-small cell lung cancer, can we predict when and for whom?;Berkovic;Acta Oncologica (Stockholm, Sweden),2015

4. Intra-patient variability of tumor volume and tumor motion during conventionally fractionated radiotherapy for locally advanced non-small-cell lung cancer: a prospective clinical study;Bosmans;International Journal of Radiation Oncology*Biology*Physics.,2006

5. The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC);Brahmer;J Immunother Cancer,2018

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predicting personalised and progressive adaptive dose escalation to gross tumour volume using knowledge-based planning models for inoperable advanced-stage non-small cell lung cancer patients treated with volumetric modulated arc therapy;Biomedical Physics & Engineering Express;2022-03-04